Video: 3 stem cell businesses at MSC2009

MSC2009, the regenerative medicine and adult stem cell therapy conference, on Monday started a three-day gathering that features a largely academic audience from as far away as Brazil, Iran and Russia to discuss innovations and research in the field.

CLEVELAND, Ohio —MSC2009, the regenerative medicine and adult stem cell therapy conference, on Monday started a three-day gathering that features a largely academic audience from as far away as Brazil, Iran and Russia discussing innovations and research in the field.

Amid the mix of hospitals, universities and research institutions displaying some of their latest research are both stem-cell startups and more established businesses, including Athersys and Pfizer, as well as stem-cell investors such as Toucan Capital.

The conference ends on Wednesday with a discussion of ways to commercialize mesenchymal stem cells, the stem cell that’s the conference’s namesake that has the ability to grow into several different kinds of cells.

Watch the embedded videos for further examples of businesses attending and displaying research at the conference.

Pluristem Therapeutics (above right) is a publicly traded company that uses adult stem cells and is developing its first treatment, which would address peripheral artery disease. In addition, the company thinks it can development product to help other afflictions including Crohn’s disease, multiple sclerosis and ischemic stroke.

Its peripheral artery disease treatment, PLX-PAD, is in the midst of Phase I clinical trials in the United States and Europe, and the company planned to present details of that study at the conference.

VitaCyte (top left) is a startup cell-isolation company that has started using stem cells in its product lines, which include manufacturing reagents, kits and purified cells to be used in the academic or commercial setting. The company uses enzymes to isolate certain cells in the hopes of speeding the production and discovery process in a lab.

General Biotechnology (right) is developing preservation methods for an array of cell types including stem cells. The company makes a series of devices dealing with stem cells, including a biomaterial that helps support fragile cells, and products that harvest and test stem cells taken from umbilical cord blood.

Shares0
Shares0